{
}
Legal & General Investment Management offers two significant ETFs, L&G Healthcare Breakthrough and L&G Pharma Breakthrough, targeting growth in the healthcare and pharmaceutical sectors. These medium-high risk products can enhance diversified portfolios, especially in light of ongoing interest in medical research post-Covid-19. The iShares Healthcare Innovation UCITS ETF stands out on the Italian stock exchange, reflecting strong performance and a focus on healthcare innovation.
The new Minister of Health faces critical challenges, including chronic overcrowding in emergency departments, a widening healthcare deficit projected at €11.4 billion by 2024, and ongoing medical desertification. Promises of reforms, such as task delegation to healthcare professionals and direct access to specialists, remain unfulfilled amid rising healthcare costs and political turmoil. Additionally, contentious issues like the Aide Médicale d'Etat scheme and a stalled bill on assisted dying complicate the landscape for healthcare reform in France.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
investing in healthcare and pharmaceutical etfs for long term growth opportunities
AstraZeneca PLC
Novartis AG
Sanofi
CHE
USA
GBR
BlackRock
Legal & General Investment Management
Show more
09:00 01.10.2024
challenges facing new health minister amid rising costs and access issues
09:00 22.09.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: